인쇄하기
취소

GC Pharm acquires approval of ‘Glargia’ referencing insulin glargine

Published: 2018-03-13 16:07:28
Updated: 2018-03-13 16:07:28

GC Pharm(CEO Eun-Cheol Huh) announced on the 9th that the company acquired approval of ‘Glargia(insulin glargine),’ an antidiabetic biosimilar(bioequivalently tested) from the Ministry of Food and Drug Safety.

The original product of ‘Glargia’ is ‘Lantus’ developed by Sanofi, a multinational pharmaceutical company, which is a medicinal drug which made over 4.6 billion euros last year in the wo...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.